Literature DB >> 28928158

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Mark Yarchoan1, Dongmei Xing1, Lan Luan2, Haiying Xu1, Rajni B Sharma1, Aleksandra Popovic1, Timothy M Pawlik3, Amy K Kim1, Qingfeng Zhu1, Elizabeth M Jaffee1, Janis M Taube1, Robert A Anders4.   

Abstract

Purpose: Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies.Experimental Design: To characterize the immune microenvironment in HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1-positive, and LAG-3-positive lymphocytes, CD163-positive macrophages, and PD-L1 expression in tumor and liver background from 29 cases of resected HCC.
Results: Expression of CD8 was reduced in tumor, and expression of CD163 was reduced at the tumor interface. Positive clusters of PD-L1 expression were identified in 24 of 29 cases (83%), and positive expression of LAG-3 on tumor-infiltrating lymphocytes was identified in 19 of 29 cases (65%). The expression of both PD-L1 and LAG-3 was increased in tumor relative to liver background. No association between viral status or other clinicopathologic features and expression of any of the IHC markers investigated was noted.Conclusions: LAG-3 and PD-L1, two inhibitory molecules implicated in CD8 T-cell tolerance, are increased in most HCC tumors, providing a basis for investigating combinatorial checkpoint blockade with a LAG-3 and PD-L1 inhibitor in HCC. Clin Cancer Res; 23(23); 7333-9. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28928158      PMCID: PMC5881396          DOI: 10.1158/1078-0432.CCR-17-0950

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

Authors:  Julien Calderaro; Benoît Rousseau; Giuliana Amaddeo; Marion Mercey; Cécile Charpy; Charlotte Costentin; Alain Luciani; Elie-Serge Zafrani; Alexis Laurent; Daniel Azoulay; Fouad Lafdil; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

2.  PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

Authors:  Feng Shi; Ming Shi; Zhen Zeng; Rui-Zhao Qi; Zhen-Wen Liu; Ji-Yuan Zhang; Yong-Ping Yang; Po Tien; Fu-Sheng Wang
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Authors:  Qiang Gao; Xiao-Ying Wang; Shuang-Jian Qiu; Ichiro Yamato; Masayuki Sho; Yoshiyuki Nakajima; Jian Zhou; Bai-Zhou Li; Ying-Hong Shi; Yong-Sheng Xiao; Yang Xu; Jia Fan
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

7.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Authors:  Bruno Sangro; Carlos Gomez-Martin; Manuel de la Mata; Mercedes Iñarrairaegui; Elena Garralda; Pilar Barrera; Jose Ignacio Riezu-Boj; Esther Larrea; Carlos Alfaro; Pablo Sarobe; Juan José Lasarte; Jose L Pérez-Gracia; Ignacio Melero; Jesús Prieto
Journal:  J Hepatol       Date:  2013-03-04       Impact factor: 25.083

8.  Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.

Authors:  Konstantin Kazankov; Anthony Rode; Kira Simonsen; Gerda Elisabeth Villadsen; Amanda Nicoll; Holger Jon Møller; Lucy Lim; Peter Angus; Ian Kronborg; Niranjan Arachchi; Alexandra Gorelik; Danny Liew; Hendrik Vilstrup; Jan Frystyk; Henning Grønbæk
Journal:  Scand J Clin Lab Invest       Date:  2015-11-07       Impact factor: 1.713

9.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.

Authors:  Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S Orsini; Morris Sherman
Journal:  Liver Int       Date:  2015-03-25       Impact factor: 5.828

10.  Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Authors:  Evan J Lipson; Mohammed T Lilo; Aleksandra Ogurtsova; Jessica Esandrio; Haiying Xu; Patricia Brothers; Megan Schollenberger; William H Sharfman; Janis M Taube
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

View more
  42 in total

Review 1.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Imane El Dika; Danny N Khalil; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2019-07-10       Impact factor: 6.860

2.  Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.

Authors:  Jinsen Zhang; Xing Xiao; Xin Zhang; Wei Hua
Journal:  J Mol Neurosci       Date:  2020-01-31       Impact factor: 3.444

3.  Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Authors:  Ludmila Danilova; Won Jin Ho; Qingfeng Zhu; Teena Vithayathil; Ana De Jesus-Acosta; Nilofer S Azad; Daniel A Laheru; Elana J Fertig; Robert Anders; Elizabeth M Jaffee; Mark Yarchoan
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

4.  Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.

Authors:  Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-17       Impact factor: 11.740

5.  Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma.

Authors:  Dafeng Xu; Yu Wang; Kailun Zhou; Jincai Wu; Zhensheng Zhang; Jiachao Zhang; Zhiwei Yu; Luzheng Liu; Xiangmei Liu; Bidan Li; Jinfang Zheng
Journal:  Onco Targets Ther       Date:  2020-08-14       Impact factor: 4.147

Review 6.  Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.

Authors:  Guoying Zhou; Patrick P C Boor; Marco J Bruno; Dave Sprengers; Jaap Kwekkeboom
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 9.075

7.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma.

Authors:  Qian Yan; Wenjiang Zheng; Boqing Wang; Baoqian Ye; Huiyan Luo; Xinqian Yang; Ping Zhang; Xiongwen Wang
Journal:  BioData Min       Date:  2021-05-07       Impact factor: 2.522

9.  Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion.

Authors:  Jikang Yang; Zhiyuan Xing
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-29

10.  Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.

Authors:  Amy K Kim; Faiz Gani; Andrew J Layman; Sepideh Besharati; Qingfeng Zhu; Farah Succaria; Elizabeth L Engle; Feriyl Bhaijee; Maria B Goggins; Nicolas J Llosa; Timothy M Pawlik; Mark Yarchoan; Elizabeth M Jaffee; Howard C Simons; Janis M Taube; Robert A Anders
Journal:  Cancer Immunol Res       Date:  2019-03-22       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.